| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
38,016,000 |
| Market
Cap: |
458.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.58 - $16.04 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 9.6 |
| Insider 6 Months : 23.7 |
| Insider 3/6 Months : 33.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. Co. has developed a proprietary portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema. Co.'s primary focus is on developing oral plasma kallikrein inhibitors for HAE. Co. has developed its candidate sebetralstat into clinical development as a potential oral, on-demand therapy for HAE attacks. Co.'s oral product candidate, KVD824 is also being developed for potential prophylactic treatment of HAE.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
29,747 |
1,251,017 |
1,251,017 |
1,251,017 |
| Total Buy Value |
$437,281 |
$16,112,140 |
$16,112,140 |
$16,112,140 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
23 |
23 |
23 |
| Total Shares Sold |
269,594 |
397,465 |
480,380 |
511,543 |
| Total Sell Value |
$3,953,538 |
$5,390,948 |
$6,266,618 |
$6,542,756 |
| Total People Sold |
5 |
5 |
6 |
6 |
| Total Sell Transactions |
9 |
19 |
30 |
46 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Palleiko Benjamin L |
President, CFO, CBO & Secy |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,364 |
82,163 |
|
- |
|
| Audhya Paul K. |
Chief Medical Officer |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,447 |
15,794 |
|
- |
|
| Yea Christopher |
Chief Development Officer |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,205 |
39,914 |
|
- |
|
| Crockett Thomas Andrew |
CEO |
• • – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,750 |
133,677 |
|
- |
|
| Feener Edward P. |
Chief Scientific Officer |
• – – |
2023-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,205 |
68,557 |
|
- |
|
| Yea Christopher |
Chief Development Officer |
• – – |
2023-02-17 |
4 |
S |
$7.66 |
$20,889 |
D/D |
(2,727) |
35,709 |
|
-11% |
|
| Yea Christopher |
Chief Development Officer |
• – – |
2023-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,204 |
38,436 |
|
- |
|
| Audhya Paul K. |
Chief Medical Officer |
• – – |
2023-02-17 |
4 |
S |
$7.66 |
$26,136 |
D/D |
(3,412) |
9,347 |
|
-11% |
|
| Audhya Paul K. |
Chief Medical Officer |
• – – |
2023-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,446 |
6,313 |
|
- |
|
| Palleiko Benjamin L |
President, CFO, CBO & Secy |
• – – |
2023-02-17 |
4 |
S |
$7.66 |
$37,948 |
D/D |
(4,954) |
72,799 |
|
-11% |
|
| Palleiko Benjamin L |
President, CFO, CBO & Secy |
• – – |
2023-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,363 |
77,753 |
|
- |
|
| Crockett Thomas Andrew |
CEO |
• • – |
2023-02-17 |
4 |
S |
$7.66 |
$51,322 |
D/D |
(6,700) |
120,927 |
|
-11% |
|
| Crockett Thomas Andrew |
CEO |
• • – |
2023-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,749 |
127,627 |
|
- |
|
| Feener Edward P. |
Chief Scientific Officer |
• – – |
2023-02-17 |
4 |
S |
$7.66 |
$17,066 |
D/D |
(2,228) |
64,352 |
|
-11% |
|
| Feener Edward P. |
Chief Scientific Officer |
• – – |
2023-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,204 |
66,580 |
|
- |
|
| Yea Christopher |
Chief Development Officer |
• – – |
2022-11-18 |
4 |
S |
$5.44 |
$6,196 |
D/D |
(1,139) |
34,232 |
|
-61% |
|
| Audhya Paul K. |
Chief Medical Officer |
• – – |
2022-11-18 |
4 |
S |
$5.44 |
$3,928 |
D/D |
(722) |
5,946 |
|
-61% |
|
| Feener Edward P. |
Chief Scientific Officer |
• – – |
2022-11-18 |
4 |
S |
$5.44 |
$2,883 |
D/D |
(530) |
62,376 |
|
-61% |
|
| Palleiko Benjamin L |
CFO, CBO & Secretary |
• – – |
2022-11-18 |
4 |
S |
$5.44 |
$3,928 |
D/D |
(722) |
68,390 |
|
-61% |
|
| Crockett Thomas Andrew |
CEO |
• • – |
2022-11-18 |
4 |
S |
$5.44 |
$9,710 |
D/D |
(1,785) |
114,878 |
|
-61% |
|
| Yea Christopher |
Chief Development Officer |
• – – |
2022-11-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,774 |
35,371 |
|
- |
|
| Audhya Paul K. |
Chief Medical Officer |
• – – |
2022-11-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,419 |
6,668 |
|
- |
|
| Feener Edward P. |
Chief Scientific Officer |
• – – |
2022-11-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,774 |
62,906 |
|
- |
|
| Palleiko Benjamin L |
CFO, CBO & Secretary |
• – – |
2022-11-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,419 |
69,112 |
|
- |
|
| Crockett Thomas Andrew |
CEO |
• • – |
2022-11-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,805 |
116,663 |
|
- |
|
277 Records found
|
|
Page 4 of 12 |
|
|
0.13 (1.07%) 
